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Abstract
Mycobacterium tuberculosis (Mtb) resides in a long-lived phagosomal compartment that resists maturation. The manner by
which Mtb antigens are processed and presented on MHC Class I molecules is poorly understood. Using human dendritic
cells and IFN-c release by CD8
+ T cell clones, we examined the processing and presentation pathway for two Mtb–derived
antigens, each presented by a distinct HLA-I allele (HLA-Ia versus HLA-Ib). Presentation of both antigens is blocked by the
retrotranslocation inhibitor exotoxin A. Inhibitor studies demonstrate that, after reaching the cytosol, both antigens require
proteasomal degradation and TAP transport, but differ in the requirement for ER–golgi egress and new protein synthesis.
Specifically, presentation by HLA-B8 but not HLA-E requires newly synthesized HLA-I and transport through the ER–golgi.
Phenotypic analysis of the Mtb phagosome by flow organellometry revealed the presence of Class I and loading accessory
molecules, including TAP and PDI. Furthermore, loaded HLA-I:peptide complexes are present within the Mtb phagosome,
with a pronounced bias towards HLA-E:peptide complexes. In addition, protein analysis also reveals that HLA-E is enriched
within the Mtb phagosome compared to HLA-A2. Together, these data suggest that the phagosome, through acquisition of
ER–localized machinery and as a site of HLA-I loading, plays a vital role in the presentation of Mtb–derived antigens, similar
to that described for presentation of latex bead-associated antigens. This is, to our knowledge, the first description of this
presentation pathway for an intracellular pathogen. Moreover, these data suggest that HLA-E may play a unique role in the
presentation of phagosomal antigens.
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Introduction
Mycobacterium tuberculosis (Mtb) remains a leading cause of
morbidity and mortality worldwide, and is the leading cause of
death in AIDS patients [1]. Following uptake by phagocytic cells
such as macrophages and dendritic cells (DC), Mtb resides in a
modified phagosomal compartment with the characteristics of an
early endosome [2]. Mtb is able to inhibit phagosomal maturation
and lysosomal fusion, and thus survive within the host cell. The
cellular immune response is vital for controlling Mtb infection and
preventing development of active TB. Macrophage activation
through the release of pro-inflammatory cytokines IFN-c and
TNF-a by CD4
+ and CD8
+ T lymphocytes is essential for the
containment of Mtb [3]. CD8
+ T cells are uniquely able to
recognize intracellular infection, and hence may play a role in
immune surveillance through direction of the granule exocytosis
pathway to the Mtb-containing cell [4]. In humans, these cellular
mechanisms maintain latent TB infection indefinitely in 90–95%
of immunocompetent individuals. Thus, the recognition of Mtb–
infected cells by T cells is central to prevention of uncontrolled
replication. Because the phagosome is a component of the HLA-II
processing pathway, the mechanisms by which Mtb-derived
antigens are processed and presented on HLA-I molecules remain
incompletely understood.
Class I presentation of phagosome associated antigens has been
extensively studied using antigen-loaded latex beads. These studies
have delineated several distinct presentation pathways [5]. In some
cases, phagosomal antigens access the cytosol, allowing processing
to occur using the conventional Class I pathway. This pathway is
characterized by proteasomal degradation, transport of peptide
fragments into the endoplasmic reticulum (ER) by TAP (trans-
porter associated with antigen processing), ER loading onto Class I
molecules, and egress of loaded complexes through the ER-golgi
[6]. Conversely, antigens can be degraded within a vacuolar
pathway, without accessing the cytosol or ER [7]. Cathepsin S is
able to generate peptide epitopes in the vacuolar pathway [8] and
peptides are subsequently loaded onto potentially recycled Class I
molecules [9,10].
More recently, the phagosome has been implicated in the
processing and presentation of phagosomal antigens. Proteins can
access the cytosol through the phagosomal acquisition of the
retrotranslocation machinery from the ER, which serves to
transport antigens into the cytosol [11]. Proteasome generated
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into the phagosomal lumen where they are loaded onto Class I
(ER-phagosomal pathway) [12,13]. It has been suggested that ER-
derived Class I loading machinery is delivered through ER-
mediated phagocytosis and/or subsequent fusion events [14],
although there is some controversy regarding this notion [15].
Although the Class I presentation of Mtb antigens is
incompletely understood, studies demonstrate the use of multiple
pathways [4]. Mtb antigens can be processed via a cytosolic pathway
[16], potentially accessing the cytosol through a porous phagosome
[17,18]. Alternately, presentation of lipoproteins or apoptotic bodies
derived from mycobacterially-infected DCcan be processed through
a non-cytosolic pathway [19,20]. Finally, we have shown that
presentation of an antigen presented by the non-classical HLA-I
molecule, HLA-E, requires proteasomal degradation but not ER-
golgi transport, suggesting that an alternate pathway may be used
after proteasomal degradation [21]. These data are consistent with
that shown for the ER-phagosomal pathway [13].
In this report, we take advantage of CD8
+ T cell clones
restricted by both classical (HLA-B8 and HLA-B44) and non-
classical (HLA-E) Class I molecules to compare the processing and
presentation pathway for two Mtb-derived antigens. While both
classically and non-classically restricted antigens require cytosolic
processing as reflected by dependence on the proteasome and
TAP, processing of the HLA-E antigen is distinguished by the
possible use of recycled HLA-E. Characterization of the Mtb
phagosome reveals the presence of HLA-I, TAP, and protein
disulfide isomerase (PDI), and Mtb phagosomes contain HLA-
I:peptide complexes. Overall, our data argue that the Mtb
phagosome is intimately involved in presentation of Mtb antigens.
Results
Mtb antigens access the cytosol but differ in their
requirement for ER–golgi transport
To define the molecular requirements for processing and
presentation of classically and non-classically restricted Mtb
antigens, CD8
+ T cell clones generated from latent and active
tuberculosis patients were utilized. Clone D480 F6 recognizes the
9mer epitope EMKTDAATL from CFP10 (CFP103–11) in the
context of HLA-B0801 [22]. D160 1-23 is restricted by the non-
classical HLA-I molecule, HLA-E. Although we have not yet
defined the antigen or minimal epitope for this clone, it responds
to the Mtb cell wall and TX-114 soluble fractions [23]. A CD4
+ T
cell clone (D454 E12) specific for a 15mer containing amino acids
69–83 of CFP10 (CFP1069–83 unpublished data) was used as a
control.
To evaluate the antigen processing pathway, the effect of
inhibitors of proteasomal degradation (epoxomicin), ER-golgi
transport [brefeldin A (BFA)], or vacuolar ATPase activity
(bafilomycin) on processing of Mtb-derived antigens was
assessed. Human monocyte-derived DC were treated with each
inhibitor for one hour prior to infection with Mtb. Following
overnight incubation in the presence of the inhibitor, DC were
fixed and used as antigen processing cells (APC) in an IFN-c
ELISPOT assay using Mtb-specific T cell clones as indicators of
antigen presentation. Presentation of CFP103–11 was almost
completely inhibited in the presence of epoxomicin and BFA,
with no effect of bafilomycin treatment (Figure 1A). This drug
inhibition profile is consistent with the cytosolic presentation
pathway. To date, analysis of five different Mtb proteins has
shown a requirement for cytosolic processing, demonstrating that
cytosolic access is not unique to CFP10 (J. Grotzke, manuscript
in preparation). HLA-E antigen presentation was also almost
completely inhibited with epoxomicin, but only partially
inhibited in the presence of BFA (50% inhibition, Figure 1A).
These data demonstrate that although the HLA-E antigen
requires cytosolic proteasomal degradation, ER-golgi transport is
not absolutely required for prese n t a t i o n .F u r t h e r m o r e ,b a f i l o -
mycin treatment actually enhanced HLA-E antigen presentation,
suggesting that phagosomal acidification leads to destruction of
the epitope.
As a control for drug toxicity and specificity, neither epoxomicin
nor BFA interfered with Mtb-derived CFP10 presentation on
HLA-II molecules. Also, there were minimal effects of inhibitor
treatment on presentation of soluble CFP10 to the CD4
+ clone or
CFP103–11 peptide to the CD8
+ clone (Figure 1B). Overall, these
data indicate that while both classically and non-classically
restricted Mtb antigens are processed in the cytosol, these antigens
utilize distinct presentation pathways.
Presentation of Mtb antigens requires TAP transport
The requirement of proteasomal processing argues for cytosolic
access of CFP10 and the HLA-E antigen. To determine if TAP
transport is required for presentation of these epitopes, we used an
adenoviral vector expressing the TAP inhibitor ICP47 [24,25] and
assessed Mtb antigen presentation by IFN-c intracellular cytokine
staining. Infection of DC with adenovirus-ICP47 led to a 25–40%
reduction of cell surface HLA-I compared to mock or empty
vector transduced cells based on geometric mean fluorescent
intensity, while cell surface HLA-II expression was not significantly
affected (data not shown). When ICP47 expressing DC were
subsequently infected with Mtb, ICP47 inhibited presentation of
the HLA-E antigen and CFP103–11 to the HLA-E and HLA-B8
restricted clones, respectively (approximately 50%, Figure 1C). In
contrast, there was no ICP47-mediated inhibition of presentation
of either soluble or Mtb-derived CFP10 by HLA-II, nor was there
any defect in ICP47-expressing cells to present the CFP103–11
peptide (Figure 1D). These data demonstrate that TAP is required
for the presentation of these two Mtb proteins.
Author Summary
Major Histocompatibility Complex Class I (MHC-I) generally
serves to present peptides derived from cytosolic proteins
to CD8
+ T lymphocytes, thereby alerting the immune
system that the cell is infected. The machinery required for
MHC-I antigen processing and presentation is localized to
the cytosol and endoplasmic reticulum (ER). After phago-
cytosis of bacteria, it is unclear how bacterial antigens are
presented by MHC-I, as they are segregated from this
machinery. In this report, we examine processing and
presentation of two proteins derived from the intracellular
pathogen, Mycobacterium tuberculosis (Mtb). We find that
Mtb proteins are able to access the cytosol where they are
degraded by the proteasome. Mtb proteins reach the
cytosol by retrotranslocation, a process which normally
functions to transport misfolded proteins from the ER to
the cytosol. Furthermore, the Mtb phagosome contains
ER–derived members of the MHC-I peptide loading
complex, which aid in loading peptides onto MHC-I
molecules. Finally, we detect loaded HLA-I:peptide com-
plexes in the phagosome, demonstrating that loading can
occur in the Mtb phagosome. Together, these findings
suggest that the Mtb phagosome, through acquisition of
ER–derived MHC-I machinery and as a site of MHC-I
loading, plays a vital role in presentation of Mtb–derived
peptides on MHC-I.
HLA-I Processing in Mtb-Infected DC
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do not require newly synthesized HLA-E
The ER contains retrotranslocation machinery that functions to
dislocate misfolded proteins into the cytosol where they can be
degraded [26]. Recent data show that latex bead phagosomes
acquire this machinery and that retrotranslocation is required for
cross-presentation of soluble OVA [11]. To determine if Mtb
antigens require transport out of the phagosome for cytosolic
access, the Pseudomonas aeruginosa protein Exotoxin A (exoA) was
utilized. ExoA inhibits protein synthesis by ADP-ribosylation of
elongation factor-2 [27]. Through interactions with members of
the retrotranslocation machinery, exoA is also able to inhibit
retrotranslocation [11,28]. Mtb–infected DC treated with exoA
were inhibited by 80% in their ability to process and present
CFP103–11, while presentation of the HLA-E antigen was inhibited
by 45% (Figure 2A). Because exoA has multiple functions, we
sought to determine whether the effect of exoA was due to a block
in retrotranslocation or inhibition of protein synthesis. Treatment
of DC with exoA led to a dramatic inhibition of vaccinia virus-
eGFP expression (Figure 2C), showing that exoA is a potent
inhibitor of protein synthesis in primary human DC. Consistent
with its effect as an inhibitor of protein synthesis, exoA blocked the
presentation of vaccinia-expressed HIV p24 to a p24 specific
CD8
+ T cell clone (Figure 2F). These studies demonstrate that
exoA can inhibit general antigen presentation by inhibiting protein
synthesis. However, it was not clear whether this mechanism was
responsible for the inhibition of Mtb presentation.
The protein synthesis inhibitor cycloheximide was used to
examine the effect of protein synthesis on presentation of Mtb
antigens. Treatment of DC with cycloheximide inhibited presen-
tation of Mtb-derived CFP103–11 by 90%, while enhancing
presentation of the HLA-E antigen (Figure 2A). These data argue
two important points. First, exoA inhibition of HLA-E antigen
presentation is not due to inhibition of protein synthesis and is
likely an effect of retrotranslocation block. Second, newly
synthesized HLA-E is not required for antigen loading.
To determine whether retrotranslocation was involved in
CFP10 processing, the exoA inhibitor PJ34 was utilized. PJ34
binds to the catalytic domain of exoA with high affinity, thereby
inhibiting ADP-ribosylation and abrogating the effect of exoA on
protein synthesis [29]. Co-incubation of PJ34 and exoA restored
vaccinia virus-eGFP expression to 70% of levels expressed in mock
(BSA/PJ34) co-treated DC based on the geometric mean
fluorescent intensity, and only 8% fewer cells expressed eGFP in
exoA/PJ34 co-treated cells (Figure 2C). Furthermore, presentation
of endogenously expressed antigen was indistinguishable from that
of BSA or BSA/PJ34 treated controls (Figure 2F). Together, these
data confirm that PJ34 blocks the protein synthesis inhibition
activity of exoA, and demonstrate that PJ34 itself does not inhibit
protein synthesis or endogenous antigen presentation. While not as
effective as exoA alone, exoA/PJ34 inhibited Mtb-derived
CFP103–11 presentation by over 60%, and had little effect on
presentation of Mtb-derived CFP10 by HLA-II (Figure 2D).
Presentation of CFP103–11 peptide or soluble CFP10 was not
blocked by exoA or exoA/PJ34 (Figure 2B and 2E), further
controlling for toxicity of these inhibitors. In total, these data argue
that presentation of both Mtb antigens are facilitated by
retrotranslocation from the phagosome for cytosolic access.
The Mtb phagosome contains HLA-I loading accessory
molecules
Since our data demonstrate that HLA-E antigen presentation
requires TAP transport, yet is insensitive to cycloheximide and
only partially blocked by BFA, we hypothesized that peptide
loading may occur within the Mtb phagosome. To determine if
the Mtb phagosome contains proteins associated with HLA-I
peptide loading, flow organellometry was employed. Mtb
phagosomes were separated from plasma and ER membranes
using a 27% percoll gradient as modified from the protocol of
Ramachandra et al. (see Materials and Methods [30]). Figure 3A
demonstrates the localization of plasma membrane, ER mem-
branes, lysosomes, and phagosomes in the gradient. While there is
some overlap between the phagosomal and lysosomal fractions,
phagosomes are clearly separated from the ER and plasma
membrane fractions. Phagosome-containing fractions (fractions
23–28) were pooled and used for flow organellometry.
To analyze phagosomal maturation, Mtb phagosomes were
compared to phagosomes containing polystyrene-coated magnetic
beads at early (20 minute pulse, 40 minute chase, 60 minute total)
Figure 1. Mtb antigens are processed by the cytosolic pathway.
(A,B) Human monocyte-derived DC were treated with epoxomicin, BFA,
or bafilomycin for one hour before infection with Mtb H37Rv-eGFP (A)
or addition of CFP10 and CFP103–11 (B). After 15–16 hours in the
presence of the inhibitor, DC were harvested, fixed, washed extensively,
and used as APC in an IFN-c ELISPOT assay where T cell clones are
effectors. DC were added to an excess of T cells so that antigen was the
limiting factor (see Materials and Methods). The mean number of spots
produced by each clone was: D160 1-23 (228.4639.3 to Mtb–infected
DC, 19.666 to uninfected DC), D480 F6 (623.5673.7 to Mtb–infected
DC, 6.762.5 to uninfected DC), D454 E12 (453652.4 to Mtb–infected
DC, 1364.4 to uninfected DC). Data have been normalized to the
untreated control, and each bar reflects the mean6SEM of at least three
experiments per clone (*p,0.05, **p,0.01 using two-tailed Student’s t
test compared to untreated controls, except where indicated). (C,D) DC
were transduced with either empty vector or adenoviral ICP47 using
Lipofectamine 2000. After 6–26 hours, DC were washed and infected
with H37Rv-eGFP (C) or pulsed with antigen (D). Following overnight
incubation, T cell clones were added and IFN-c production was assessed
by intracellular cytokine staining. The mean percentage of IFN-c
+ clones
was: D160 1-23 (8.261.1 to Mtb–infected DC, 1.160.2 to uninfected
DC), D480 F6 (46.463.9 to Mtb–infected DC, 1.560.4 to uninfected DC),
D454 E12 (6466 to Mtb–infected DC, 0.760.3 to uninfected DC). Each
bar represents the mean6SEM of seven independent experiments.
doi:10.1371/journal.ppat.1000374.g001
HLA-I Processing in Mtb-Infected DC
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beads were gated on their distinct scatter profile (data not shown).
Early magnetic bead phagosomes were either LAMP-1
lo/2/HLA-
I
+, LAMP-1
+/HLA-I
lo/2, or double negative (Figure 3B). The
latter population likely represents unphagocytosed beads. Analysis
of the LAMP-1
lo/2/HLA-I
+ population revealed phagosomes that
are positive for the early endosomal markers rab5 and transferrin
receptor (TfR), and strongly positive for HLA-A2 and HLA-I
(Figure 3B). This population likely represents beads that have
recently been phagocytosed. Consistent with this hypothesis, this
population is absent following overnight incubation. Alternately,
the LAMP-1
+/HLA-I
lo/2 population had greatly reduced levels of
early endosomal markers after one hour and were essentially
devoid of these markers after an overnight incubation (Figure 3B).
These data demonstrate normal phagosomal maturation of inert
particles.
In contrast, flow organellometry of Mtb phagosomes revealed a
distinct phagosomal phenotype. After one hour of Mtb infection,
the LAMP-1
lo/2/HLA-I
+ population seen in magnetic bead
phagosomes was not detected (data not shown), possibly a
reflection of the smaller number of events obtained for Mtb
phagosomes. As a result, Mtb phagosomes could be accurately
gated solely based on GFP and LAMP-1 (Figure 3B). Mtb
phagosomes obtained one hour after infection contained similar or
greater levels of early endosomal markers to those seen in the
LAMP-1
+/HLA-I
lo/2 magnetic bead population (Figure 3C and
3D). However, overnight Mtb phagosomes remained positive for
rab5, TfR, and HLA-I (Figure 3B and 3C). This phenotype is
consistent with early endosomal arrest, a hallmark of the Mtb
phagosomes [2].
Having purified and phenotyped the Mtb phagosome, we asked
whether HLA-I associated loading molecules were present. In
addition to HLA-I (Figure 3), the Mtb phagosome contained
loading accessory molecules TAP1, TAP2, and PDI, as well as
proteins containing the KDEL ER retrieval sequence (Figure 4A
and 4B). These proteins were found at similar levels at one hour
and overnight, suggesting that these molecules are stable within
the Mtb phagosome. Detection of ER proteins in the Mtb
phagosome did not correlate with the total cellular levels of these
proteins in DC (Figure 4A, note TAP2 versus TAP1, calnexin, and
calreticulin). Furthermore, Mtb phagosomes were negative for
ER-resident proteins calnexin and calreticulin. These results
suggest that the presence of ER proteins was selective and not
the result of gross contamination during homogenization or
staining.
To further control for contamination, we performed a mixing
experiment in which HLA-A2 could be used to discern membrane
contamination. HLA-A2
2 DC were infected with Mtb and mixed
Figure 2. Mtb proteins require retrotranslocation for presentation. (A,B) DC were treated with exoA or cycloheximide for one hour prior to
infection with H37Rv-eGFP (A) or addition of CFP10 and CFP103–11 (B). DC were harvested, fixed, and assessed for their ability to stimulate T cell
clones by IFN-c ELISPOT as described. Each bar reflects the mean6SEM of at least three experiments. ND, not done. (C) DC were treated with exoA,
exoA/PJ34, or BSA/PJ34 for one hour prior to infection with vaccinia virus expressing eGFP. After 16–18 hours, DC were harvested and GFP expression
analyzed by flow cytometry. Data are representative of three experiments. (D,E) DC treated with exoA, BSA, exoA/PJ34, or BSA/PJ34 for one hour were
subsequently infected with H37Rv-eGFP (D) or pulsed with antigen (E) overnight, harvested, fixed, and assessed for their ability to stimulate T cell
clones by IFN-c ELISPOT. Data are representative of two experiments. (F) DC were treated with exoA, exoA/PJ34, or BSA/PJ34 for one hour prior to
infection with vaccinia virus expressing HIV p24. After 16–18 hours, DC were harvested, fixed and used to stimulate the HIV p24306–316-specific CD8
+
clone 16A7 in an IFN-y ELISPOT assay. Data are representative of two experiments.
doi:10.1371/journal.ppat.1000374.g002
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+ DC. Following homogenization and
percoll separation, phagosomes were stained with an antibody to
HLA-A2. We did not detect any HLA-A2 in the Mtb phagosome
after mixing (Figure 5A), suggesting that there is little non-specific
association of membranes with Mtb phagosomes during process-
ing. However, HLA-A2 contamination could be detected if
phagosomes were pelleted from the postnuclear supernatant
without first separating over the percoll gradient. Interestingly,
while Mtb phagosomes are positive for HLA-I (Figure 3), we did
not detect HLA-A2 in phagosomes from HLA-A2
+ DC
(Figure 5A). However, we were able to detect HLA-A2 staining
in LAMP-1
lo/2/HLA-I
+ magnetic bead phagosomes (Figure 3C)
and in lymphoblastoid cell lines (LCL) (Figure 5B). Because HLA-
A2 is expressed at much higher levels in DC than any of the ER
molecules examined, we conclude that there could only be
minimal contamination of ER proteins in our phagosomal
preparations.
Finally, we assessed the levels of cis- and trans-golgi markers
GM130 and golgin-97, respectively. Neither protein was present in
the Mtb phagosome (Figure 5C), but were detected in intact DC
Figure 3. The Mtb phagosome retains characteristics of an early endosome. (A) Representative figure showing organelle distribution after
percoll separation of homogenate from Mtb–infected DC. The plasma membrane was labeled with a PE-conjugated antibody to HLA-II prior to
homogenization and fluorescence was detected by fluorometry. For detection of ER, fractions were assessed for the presence of TAP1 and PDI by
western blot. An enzymatic assay for b-hexosaminidase was used for detection of lysosomes. Finally, fractions were examined for the presence of
H37Rv-eGFP by flow cytometry and quantified using a reference latex bead population. For flow cytometric analysis of Mtb phagosomes, the final
2 ml (fractions 23–28) of the gradient were pelleted, fixed, permeabilized, and stained with antibodies of interest. (B) Magnetic bead and Mtb
phagosomes were gated based on FSC/SSC (not shown) and then on LAMP-1/HLA-I (beads) or LAMP-1/GFP (Mtb). Arrows indicate the gated
population. Analysis of phagosome maturation on one hour LAMP-1
lo/2/HLA-I
+ magnetic bead phagosomes (top panel), one hour LAMP-1
+/HLA-I
lo/2
magnetic bead phagosomes (second panel), overnight LAMP-1
+ magnetic bead phagosomes (third panel), and overnight Mtb phagosomes (bottom
panel). Plots include isotype staining (shaded histograms) as well as staining with the indicated antibody (red lines). The amplified HLA-I signal on the
HLA-I-FITC gated events is due to the use of primary and secondary antibody combination, with which we routinely see up to a log shift in signal over
conjugated primary. (C,D) Quantitative analysis of phagosomes over time. The percent positive number represents Overton cumulative histogram
subtraction of the isotype control from the indicated stain. Each bar represents the mean6SEM of three experiments per timepoint.
doi:10.1371/journal.ppat.1000374.g003
Figure 4. The Mtb phagosome contains HLA-I loading accessory molecules. (A) DC were pulsed with H37Rv-eGFP for 20 minutes, washed,
and incubated for 40 minutes. Phagosomal fractions were prepared as in Figure 3 and stained with the indicated antibodies (top panel). Intact DC
were fixed, permeabilized, and stained with the indicated antibodies (bottom panel). Data are representative of three experiments. (B) Quantitative
analysis of Mtb phagosomes over time. The percent positive number represents Overton cumulative histogram subtraction of the isotype control
from the indicated stain. Each bar represents the mean6SEM from three experiments per timepoint.
doi:10.1371/journal.ppat.1000374.g004
HLA-I Processing in Mtb-Infected DC
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associated loading accessory molecules are bona fide constituents
of the Mtb phagosome.
Loaded HLA-I:peptide complexes are present in the Mtb
phagosome
To assess whether peptide loading occurs in the Mtb
phagosome, percoll-separated fractions from Mtb–infected DC
were tested for their ability to stimulate CD8
+ T cell clones in the
absence of DC by IFN-c ELISPOT. Mtb phagosomes were
purified by percoll density gradient and, as was described above,
were localized to fractions 23–28 and were well-separated from
plasma membrane and ER positive fractions. Percoll separated
fractions were freeze-thawed to expose lumenal HLA-I, and
incubated with Mtb-specific CD8
+ T cell clones restricted by
HLA-E or HLA-B44. For this experiment, we used a HLA-B44-
restricted T cell clone specific for CFP102–11, which we have
previously shown is sensitive to BFA and lactacystin and requires
TAP transport [16], similar to CFP103–11. As expected, both
clones responded to plasma membrane/ER fractions, revealing
the presence of loaded HLA-I:peptide complexes in these cellular
fractions (Figure 6A). Loaded HLA-E:peptide complexes were also
detected in phagosome-containing fractions as early as one hour
post-infection, suggesting that peptide loading can in fact occur
within the Mtb phagosome, although we cannot formally exclude
loading in another compartment and subsequent trafficking to the
phagosome. Fewer HLA-B44:CFP102–11 complexes were detected
within phagosome fractions, suggesting that less CFP102–11
loading occurs within the phagosome. These data are consistent
with BFA data, showing that almost all CFP102–11 processing and
presentation requires ER-golgi transport [16].
To exclude the possibility that stimulation was due to
contamination of ER- or plasma membrane-derived HLA-
I:peptide complexes, T cells were stimulated with fractions from
CFP102–11 peptide-pulsed DC. No responses were detected in the
high density fractions (Figure 6B). To exclude the possibility that
pre-formed peptide was simply being presented by T cells, we
tested fractions from Mtb–infected, HLA-I mismatched DC for
their ability to stimulate Mtb-specific CD8
+ clones. Clone D481
C10, which responds to CFP1075–83 in the context of HLA-B1502
[22] was stimulated by plasma membrane/ER fractions from
Mtb–infected D481 DC (HLA-B15
+/HLA-B44
2). No HLA-
B44:CFP102–11 responses were detected (Figure 6C). These data
suggest that HLA-I loading can occur in the Mtb phagosome and
is enhanced for HLA-E.
To quantitatively assess the degree of plasma membrane
contamination of the phagosome-containing fractions, plasma
membrane was labeled with a PE-conjugated antibody to HLA-II
prior to homogenization, and presence of plasma membrane in
each fraction was assessed by flow cytometry. Phagosome-
containing fractions contained some PE
+ plasma membranes,
with very little associated with phagosomes (Figure 6D, note lack
of a distinct double positive population). The number of plasma
membrane particles in each fraction was quantified using a
reference bead population (see Materials and Methods). Consistent
with data obtained in Figure 3A, the number of plasma membrane
particles were strongly associated with the plasma membrane
peak, and decreased in every fraction thereafter (Figure 6E). These
data, then, suggest that the IFN-c response in the phagosomal
fractions cannot be attributed to gross plasma membrane
contamination, a conclusion strengthened by the relative enrich-
ment of HLA-E specific activity in the phagosomal fractions.
HLA-E is enriched in phagosomal fractions after Mtb
infection
Since there was an enhanced HLA-E specific response to the Mtb
phagosome (Figure 6), we studied whether HLA-E may be
preferentially presentwithin the phagosome. After percollseparation
of homogenates from Mtb–infected DC, HLA-I from plasma
membrane or phagosomal fractions was immunoprecipitated with
Figure 5. Mtb phagosomes contain minimal contamination. (A) HLA-A2
2 or HLA-A2
+ DC were infected with H37Rv-eGFP for 20 minutes,
washed, and incubated for an additional 40 minutes. HLA-A2
2 DC were mixed with uninfected HLA-A2
+ DC, homogenized, and homogenate
separated using 27% percoll as described or pelleted without percoll separation. Phagosomes were stained with an antibody to HLA-A2. Shaded
histograms represent isotype staining. Data are representative of three experiments. (B) HLA-A2
2 or HLA-A2
+ LCL were fixed, permeabilized, and
stained with an antibody to HLA-A2. (C,D) Mtb phagosomes (C) or intact DC (D) were analyzed for the presence of cis- and trans-golgi markers GM130
and golgin-97, respectively. Data in C are representative of three experiments each after a 40 minute or overnight chase. Data in D are representative
of two experiments.
doi:10.1371/journal.ppat.1000374.g005
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each compartment were compared by western blot using
three different HLA-I antibodies. Because HLA-I levels are
greatly increased on the plasma membrane compared to the
phagosome, the immunoprecipitate from plasma membrane was
normalized to give roughly equivalent intensity bands for total
HLA-I levels (HC10). While the blots for HLA-A2 are similar to
that for HC10, the intensity of HLA-E is increased over seven-
fold in the phagosome (Figure 6F). These data support the
functional data that HLA-E complexes are more easily detected
Figure 6. HLA-E:peptide complexes are present in phagosomal fractions. (A,B) DC were pulsed with H37Rv-eGFP or CFP102–11 peptide and
the homogenate was separated using 27% percoll as described. Each fraction was freeze-thawed and tested for its ability to stimulate D160 1-23 (A)
or D160 1-1B (A&B) CD8
+ T cell clones in the absence of additional APC. IFN-c production was measured using ELISPOT. The mean6SEM of duplicate
wells is presented. Data are representative of four experiments at various timepoints in A, and four experiments after a one hour peptide pulse in B.
(C) Plasma membrane/ER fractions from Mtb–infected DC (HLA-B15
+/HLA-B44
2) were incubated with HLA-I matched or mismatched CD8
+ T cell
clones and IFN-c production was measured using ELISPOT. The mean6SEM of duplicate wells is presented and data are representative of three
experiments done similarly. (D,E) Individual fractions were analyzed by flow cytometry to assess HLA-II-PE (plasma membrane) and H37Rv-eGFP
fluorescence. Selected fractions are shown (D) including the peak plasma membrane fraction (#8) and phagosomal fractions (#24–27). Prior to flow
cytometry, fractions were mixed with a reference latex bead population at a known concentration. Equal numbers of latex bead events were
collected for all fractions and used to quantify the number of plasma membrane and phagosome particles (E) as described in Materials and Methods.
(F) HLA-I was immunoprecipitated from plasma membrane or phagosome fractions using W6/32. After dilution of the plasma membrane sample to
give similar levels of HC10 staining, the presence of HLA-I alleles was assessed using antibodies to pan-HLA-I (HC10), HLA-A2 (HCA2), and HLA-E
(MEM-E/02). The numbers below blots indicate the relative intensity of the bands as described in Materials and Methods.
doi:10.1371/journal.ppat.1000374.g006
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trafficking or retention of certain HLA-I alleles to the Mtb
phagosome. Additionally, these data are not consistent with
simple contamination.
HLA-I, loading machinery, and HLA-I:peptide complexes
are present in highly pure Mtb phagosomes
To further control for contamination of Mtb phagosomes, a
method was devised to magnetically purify Mtb phagosomes,
thereby generating a highly pure phagosomal preparation. After
biotinylation of Mtb cell surface proteins, the bacteria were
washed and incubated with streptavidin-coated supraparamag-
netic particles (approximately 50 nm diameter). DC were infected
with the labeled bacteria, and phagosomes were purified by
passing the postnuclear supernatant directly over a magnetic
column. The resulting population is very pure as seen by electron
microscopy (EM, Figure 7A), which shows the presence of Mtb
surrounded by an intact phagosomal membrane and little
Figure 7. HLA-I, loading machinery, and HLA-I:peptide complexes are present in highly pure Mtb phagosomes. (A) Phagosomes were
isolated by percoll gradient or magnetic purification and prepared for electron microscopy as described in Materials and Methods. (B) Magnetic bead-
isolated phagosomes were analyzed by flow cytometry to assess HLA-II-PE (plasma membrane) and H37Rv-eGFP fluorescence as described in
Materials and Methods and Figure 6. The events shown represent a small proportion of the population of phagosomes isolated and the experiment is
representative of three experiments. (C) DC were pulsed with magnetically-labeled H37Rv-eGFP for 20 minutes, washed, and incubated for 18 hr.
After magnetic separation of Mtb phagosomes, flow organellometry was performed as described previously. Data are representative of three
experiments. (D) Magnetically-isolated Mtb phagosomes were freeze-thawed and tested for their ability to stimulate D160 1-23 CD8
+ T cell clones in
the absence of additional APC. IFN-c production was measured using ELISPOT. Data are representative of two experiments.
doi:10.1371/journal.ppat.1000374.g007
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few contaminating particles present in the magnetic fraction were
identified as free magnetic beads. When contamination of plasma
membrane was assessed by flow organellometry, less than 2% of
the purified phagosomes were associated with PE
+ plasma
membranes (Figure 7B). In comparison, 5–7% of the percoll-
separated phagosomes were associated with plasma membrane
(Figure 6C). Therefore, based on EM and flow organellometry,
this purification protocol results in phagosomes that are at least
98% pure.
The presence of HLA-I and members of the peptide loading
complex were next examined by flow organellometry. HLA-I,
PDI, and TAP2 were all detected on the magnetically-purified 18-
hour Mtb phagosomes, while calreticulin was excluded (Figure 7C),
similar to the results presented in Figures 3–5. In total, these data
establish the presence of ER proteins that aid in HLA-I
presentation in the Mtb phagosome.
Finally, magnetically-purified phagosomes were used to exam-
ine the presence of loaded HLA-E:peptide complexes, as described
in Figure 6. The addition of freeze-thawed, magnetically-purified
Mtb phagosomes to D160 1-23 led to IFN-c production
(Figure 7D), demonstrating the presence of loaded HLA-E:peptide
complexes in the Mtb phagosome. Unfortunately, the lower
phagosomal yields obtained using this protocol precluded us from
simultaneously testing the responses of both CD8
+ T cell clones.
Overall, these results confirm the data presented in Figures 3–6,
and provide further evidence that the presence of ER proteins and
loaded HLA-I:peptide complexes are not due to contaminating
membranes in the percoll separated phagosomes.
Discussion
Here, we find that presentation of both the HLA-E antigen and
CFP10 require proteasomal degradation and TAP transport.
Presentation of both antigens is blocked by the retrotranslocation
inhibitor exoA. In contrast to presentation on HLA-B8, HLA-E
presentation is only partially BFA-sensitive and is enhanced with
cycloheximide treatment. We find the presence of HLA-I and ER-
derived HLA-I loading accessory molecules PDI and TAP in the
Mtb phagosome. Accordingly, we are able to detect loaded HLA-
E:peptide complexes in the Mtb phagosome.
These data demonstrate that both classically and non-classically
presented Mtb proteins require cytosolic access for presentation.
Both epitopes are generated by the cytosolic proteasome and
require subsequent TAP transport. The cytosolic requirement for
presentation of these antigens differs from that previously shown
for the presentation of the Mtb 19 kDa lipoprotein [19] and for
cross-presentation of apoptotic bodies from mycobacterially-
infected cells [20], demonstrating the potential for multiple
presentation pathways. In this regard, the pathway by which a
specific antigen is processed likely depends on the characteristics of
the antigen (i.e. secreted versus non-secreted versus lipoprotein),
the nature of delivery (i.e. apoptotic body versus Mtb bacilli), and
specific properties of the associated HLA-I allele (see below). In the
murine model, a dominant pathway has not been elucidated. We
have examined the processing pathway of an additional seven
HLA-I Mtb-derived epitopes and found that all are presented
using the cytosolic pathway (J. Grotzke, manuscript in prepara-
tion). These findings suggest that Mtb proteins are preferentially
processed in the cytosol in Mtb–infected DC.
A recent report has shown that Mtb is able to escape the
phagosome after 48–96 hours of infection [31], a process which
requires the Region of Difference 1 (RD1 [32]). This would give
Mtb antigens access to the cytosol where they would be processed
as endogenously expressed antigens. The authors hypothesized
that this may increase antigen presentation. We have examined
Mtb–infected DC at less than 18 hours post infection, a time when
all Mtb should be present within the phagosome. Furthermore, we
and others have shown that RD1 is not required for presentation
of Mtb antigens on class I molecules [16,33]. This excludes
phagosomal escape as a confounding factor in our interpretations.
Our data argue that the Mtb phagosome is a compartment that
aids in presentation of phagosome-derived antigens, similar to that
demonstrated using latex beads [11–13,34]. Presentation of both
Mtb antigens examined is blocked by the retrotranslocation
inhibitor exoA, suggesting that phagosomes acquire the ER-
derived retrotranslocation machinery which serves to transport
Mtb proteins into the cytosol. The finding that exoA blocks
protein synthesis and endogenous antigen processing of vaccinia-
delivered antigens is conflicting with published data using the DC-
like cell line, KG-1 [11]. This discrepancy may be due to the use of
a cell line versus ex vivo generated DC, as we saw only minor
differences in vaccinia-eGFP expression and vaccinia-expressed
antigen presentation in LCL treated with exoA (data not shown).
The NAD analog PJ34 was used to uncouple the protein synthesis
and retrotranslocation inhibition functions of exoA. When primary
DC were co-treated with exoA and PJ34, GFP expression and
endogenous antigen presentation were restored, while the
inhibition of Mtb antigen presentation was unaffected. These
data strongly argue that the exoA inhibition is due to retro-
translocation block, and that the retrotranslocation machinery
plays a role in presentation of Mtb antigens.
The Mtb phagosome also contains members of the HLA-I
peptide loading complex and loaded HLA-I:peptide complexes,
suggesting that the phagosome is a site for HLA-I loading. While
ICP47 inhibition demonstrates a role for TAP transport of both
Mtb antigens, we cannot discern whether the blockade occurs at
the ER or phagosomal membrane. The detection of TAP and
loaded HLA-E in the Mtb phagosome indirectly argues that
phagosomal TAP is functional. We have not addressed how ER
proteins are delivered to the Mtb phagosome. Although the notion
of ER-mediated phagocytosis, and particularly the relative
contribution of ER membrane to the phagosomal membrane
remains controversial [14,15], multiple groups have detected
members of the MHC-I peptide loading complex and functional
TAP, glycosylation, and retrotranslocation machinery in latex
bead phagosomes [11–14,34]. Several reports have not detected
the presence of ER proteins within latex bead or mycobacterial
phagosomes [15,31]. In this regard, the use of flow cytometry has
enhanced our ability to find ER proteins in the Mtb phagosome, as
this approach allows us to detect low protein levels and analyze
thousands of events per experiment, using objective software to
analyze results. Furthermore, we have included a variety of
controls to address the possibility of plasma membrane or ER
contamination of Mtb phagosome preparations. Our data
demonstrate that the detection of HLA-I, loading accessory
molecules, and HLA-I:peptide complexes are true components of
the Mtb phagosome.
Although both CFP10 and the HLA-E antigen require cytosolic
processing, our data demonstrate that these two antigens use
distinct cytosolic pathways. After proteasomal degradation, both
peptide fragments require TAP transport. CFP103–11 then follows
a pathway that is characteristic of presentation of endogenous
proteins. In contrast, the HLA-E antigen follows a different
pathway, being incompletely blocked by BFA and enhanced by
cycloheximide. This argues that newly synthesized HLA-E is not
required for loading, and that once loaded, HLA-E:peptide
complexes do not require transport through the ER-golgi to the
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complexes, but fewer HLA-B44:CFP102–11 complexes within the
Mtb phagosome. Presentation of latex bead delivered OVA
through the ER-phagosomal pathway has been shown to be only
partially BFA sensitive [13], similar to the data presented here. Of
note, one other group has reported BFA-independent presentation
of unidentified Mtb antigen(s), although the role of the proteasome
was not examined [35]. Because nascent HLA-E is not required
for presentation, we believe that recycled HLA-E is loaded in the
phagosome. This is similar to what has been postulated for MHC-I
loading in the vacuolar pathway [9,10]. Ackerman et al. reported
that the majority of latex bead phagosome-associated MHC-I is
endoglycosidase H resistant (post-golgi [34]). This is consistent
with our hypothesis that recycled HLA-E can be loaded in the
phagosome.
Our finding of divergent processing pathways during Mtb
infection, and the enhanced availability of HLA-E in the
phagosome suggests that HLA-E may play a specialized role in
the presentation of phagosomal antigens. The ten Mtb epitopes
that we have examined are presented by 8 different HLA-I alleles
and we have yet to find another antigen that is as incompletely
inhibited by BFA as the HLA-E antigen (J. Grotzke, manuscript in
preparation [16]). Examining the requirement for new protein
synthesis will allow us to further estimate the amount of
phagosomal loading for each epitope and HLA-I allele. Whether
HLA-E is specifically targeted to the phagosome or is delivered by
enhanced recycling or is selectively retained remains to be
determined. However, it is intriguing to note that HLA-E and
the murine ortholog Qa-1
b are less stable than classical MHC-I
molecules and have a higher turnover rate [36,37]. Together,
these data argue that HLA-E may uniquely participate in
surveillance of phagosomal antigens.
In conclusion, we have examined in detail the presentation of
two Mtb-derived antigens. We find that both antigens require
cytosolic processing but differ in the overall pathway. Similar to
latex bead phagosomes, the Mtb phagosome acquires components
that are required for Class I presentation. These data suggest that
in addition to its role in innate immunity, the phagosome aids to
alert the cellular adaptive immune system to the presence of
intracellular bacteria. Our data also suggest a potentially unique
role for HLA-E in surveillance and presentation of phagosomal
antigens. Because HLA-E exhibits low polymorphism, preferential
surveillance of the phagosome by HLA-E may serve to present
conserved bacterial peptides. In total, these findings demonstrate
that cellular mechanisms are in place to ensure that antigens from
pathogens that reside in the phagosome are not excluded from the
Class I pathway.
Materials and Methods
Reagents and antibodies
Inhibitors of antigen processing were obtained from EMD
Biosciences (epoxomicin, bafilomycin, and PJ34), Sigma (cyclo-
heximide and Pseudomonas aeruginosa exotoxin A), and Invitrogen
(brefeldin A). The following antibodies were used for flow
cytometry: TAP1, TAP2, EEA-1, rab5, GM130, HLA-A2,
LAMP-1-PE (BD Biosciences), PDI, KDEL, calreticulin (Stress-
gen), HLA-I-FITC or unconjugated (B9.12.1, Coulter), TfR
(Biosource), calnexin (Affinity Bioreagents), golgin-97 and goat
anti-mouse IgG Alexa Fluor-647 (Invitrogen). Soluble CFP10
protein was provided by Corixa. CFP10 peptides were synthesized
by Genemed Synthesis Inc. Magnetic particles (2.8 mm tosylacti-
vated beads, Dynal) were coupled to BSA according to the
manufacturer’s protocol before addition to DC.
Bacteria, virus, and cells
Mycobacterium tuberculosis H37Rv-eGFP was grown in Middleb-
rook 7H9 broth supplemented with Middlebrook ADC (Fisher),
0.05% Tween-80, 0.5% glycerol, and kanamycin (50 mg/ml).
Before infection, bacteria were sonicated, passaged 15 times
through a tuberculin syringe, and sonicated again to obtain a
single cell suspension.
Adenoviral vectors [25] were provided by Dr. David Johnson
(OHSU). Vaccinia virus expressing HIV p24 was provided by
Therion Biologics Corp. and vaccinia virus expressing eGFP was
provided by Corixa.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Oregon Health & Sciences
University and the Portland VA hospitals (IRB00000186). All
patients provided written informed consent for the collection of
samples and subsequent analysis. PMBC were obtained from
normal human donors via leukapheresis according to IRB
approved protocols and processed as previously described [23].
DC were generated by culturing adherent PBMC for 5 days in the
presence of GM-CSF (10 ng/ml, Amgen) and IL-4 (10 ng/ml,
R&D systems) in RPMI (Gibco) supplemented with 10% pooled
human serum (HS), L-glutamine (4 mM, Gibco), and gentamicin
(50 mg/ml, Invitrogen).
T cell clones
Clones D160 1-1B, D160 1-23, D480 F6, and D481 C10 have
been previously described [22,23,38]. D454 E12 is a CFP10-
specific CD4
+ clone (unpublished). Clone 16A7 is a HLA-B44
restricted CD8
+ T cell clone that responds to amino acids 306–316
(AEQASQEVKNW) of HIV p24 [39]. T cell clones were
expanded as previously described [16], except that some of the
expansions were done in Stemline T cell expansion media (Sigma)
supplemented with 1% FBS (Hyclone) and 4 mM L-glutamine.
ELISPOT Assay
IFN-c ELISPOT was performed as previously described [23].
Inhibition of antigen presentation
Day 5 DC were plated in 24 well ultra low adherence (ULA)
plates (Costar) at 5610
5/well in RPMI/10% HS supplemented
with GM-CSF and IL-4. DC were pretreated with inhibitors
(1 mM epoxomicin, 0.1 mg/ml BFA, 0.2 mM bafilomycin, 10 mg/
ml cycloheximide, 10 mg/ml exoA, or 10 mg/ml exoA with 200
fold molar excess PJ34) for one hour before infection with H37Rv-
eGFP (MOI=20), vaccinia virus (MOI=2), or addition of antigen
(0.5–1 mg/ml CFP10, 1 mg/ml CFP103–11). In experiments using
exoA/PJ34 or BSA/PJ34, these compounds were co-incubated at
room temperature for 30 minutes before addition to DC.
DC were harvested after 15–16 hours of infection, pelleted and
fixed with 0.5% paraformaldehyde for 15 minutes. The reaction
was stopped with an equal volume of 0.4 M Lysine or RPMI/10%
HS and DC were washed extensively with RPMI/10% HS. Fixed
DC were then added to an IFN-c ELISPOT plate at varying
quantities so that antigen was the limiting factor (25,000 Mtb–
infected DC/well for CD8
+ clones, 1,000 Mtb–infected DC/well
for CD4
+ clones, and 2,000 Ag-pulsed DC/well for both CD4
+
and CD8
+ clones). This MOI and number of DC per well was
used to obtain strong T cell responses which are still able to be
inhibited with blockers of antigen presentation, as previously
reported [16,40]. T cells clones were added in excess at 10,000/
well and plates were incubated at 37uC for 18 hours before
development.
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DC were tranduced with adenovirus using Lipofectamine 2000
(Invitrogen) as previously described [16]. After 6–26 hours of
incubation with adenovirus, media was removed and replaced
with RPMI/10% HS containing H37Rv-eGFP (MOI=15–20 for
CD8
+ T cell clones, 0.2–20 for CD4
+ clones) or antigen (0.25 mg/
ml CFP103–11, 0.005 mg/ml CFP10) and incubated overnight at
37uC. After 15–16 hours, media was removed and T clones were
added (1.5610
5/well) in the presence of BFA (10 mg/ml). After a
six hour stimulation, T cell clones were harvested, fixed with 1%
paraformaldehyde, and stained with antibodies to CD3 (UCHT1,
BD Biosciences) and IFN-c (Coulter) in the presence of 0.2%
saponin (Sigma). Cells were analyzed using a FACSCalibur or
LSR II (Becton Dickinson).
Flow organellometry
DC were added to a 6 well ULA plate (2.5610
6/well) in RPMI/
10% HS supplemented with GM-CSF (10 ng/ml) and IL-4
(10 ng/ml) and allowed to adhere. H37Rv-eGFP (MOI=5–7.5)
or magnetic beads (1–10/cell) were added to wells and centrifuged
onto DC at 22uC for 5 min. DC were then incubated for an
additional 15 min at 37uC for a total pulse time of 20 min. DC
were placed on ice and washed with cold RPMI and incubated for
an additional 40 min or overnight at 37uC. DC were washed on
ice with cold RPMI and harvested. DC were resuspended in ice
cold homogenization buffer (0.25 M sucrose, 10 mM Hepes,
pH=7.4) containing protease inhibitors (Complete Mini protease
inhibitor cocktail tablet, Roche) and homogenized by passaging
through a 23 gauge needle. At this point, magnetic beads were
purified using a particle concentrator (Dynal). For Mtb phago-
somes, intact cells and nuclei were removed by two spins at 2006g,
4uC. Postnuclear supernatant was layered onto 27% percoll
(Amersham) and centrifuged for one hour at 4uC, 36,0006gi na
70.1Ti rotor (Beckman).
The phagosome-containing fractions (final 2 ml of gradient)
were pelleted, fixed with 1% paraformaldehyde on ice for
15 minutes, washed, and stained with primary antibodies (5 mg/
ml) for 40 min on ice in the presence of 0.2% saponin, 2% HS, 2%
goat serum, and 0.5% FBS. After washing, goat anti-mouse-IgG-
Alexa Fluor-647 was added (1:1000) and incubated for 40 min.
Phagosomes were then washed twice and stained with anti-LAMP-
1-PE and anti-HLA-I-FITC for 40 min. Phagosomes were washed
and analyzed using a FACSCalibur or LSR II.
The percentage of positive phagosomes was determined using
the Overton histogram subtraction method in Flowjo software
(Treestar), which compares the isotype- and experimentally-
stained populations. The values obtained from this analysis are
shown in Figures 3 and 4. We also analyzed each experiment by
setting the isotype gate so that 5% of the events are positive, and
then applied this gate to stained samples. After subtracting the
isotype value, these numbers gave almost identical results as that
seen using Overton analysis (data not shown).
Subcellular fractionation
DC were plated in 6 well ULA plates as above. H37Rv-eGFP
(MOI=7.5) was added to wells and centrifuged onto DC for
5 min at 22uC. DC were incubated for an additional hour or
overnight, without washing. After infection, DC were placed on
ice, washed with cold RPMI, and harvested. Before homogeniza-
tion, DC were labeled with a PE-conjugated antibody to HLA-II
(Coulter) to track plasma membrane. Excess antibody was
removed by centrifugation, cells were resuspended in homogeni-
zation buffer, homogenized and separated on a percoll gradient as
above. The percoll gradient was manually fractionated into 28
fractions (332 ml each).
Lysosomes were detected using an enzymatic assay to detect b-
hexosaminidase activity as previously described [30]. ER contain-
ing fractions were identified using western blot for PDI and TAP1
(Stressgen). For plasma membrane and phagosome detection,
fractions were fixed with paraformaldehyde. Plasma membrane
was detected using a fluorometer with an excitation filter of
530612.5 nm and emission filter of 590617.5 nm. Phagosomes
were detected using a flow-based assay, where fixed fractions were
mixed with a reference population of 2 mm latex beads
(Polysciences) at a known concentration and analyzed using a
FACSCalibur or LSR II. Phagosomes were detected based on
GFP fluorescence and quantified using the ratio of GFP
+ events to
latex beads. Plasma membrane was also quantified using this assay
and gave similar results to fluorometer data. Quantification of
organelles was done using the following equation: ratio of PE
+ or
GFP
+ to latex beads * #beads/ml * dilution factor * fraction
volume
For detection of loaded HLA-I:peptide complexes, fractions
were frozen overnight at 280uC and thawed. 20–45 ml fractions
were added to duplicate wells of an ELISPOT plate containing
20,000 T cell clones and incubated for 18–48 hours at 37uC
before development.
Magnetic purification of Mtb phagosomes
Magnetic labeling of H37Rv-eGFP was carried out as follows.
After two washes in PBS, H37Rv-eGFP was incubated with sulfo-
NHS-biotin (1 mg/ml, Pierce) in PBS for 30 minutes at room
temperature. The reaction was stopped with 0.1 M glycine and
the bacteria washed twice in PBS/0.05% Tween-80. After 5–10
passages through a 27 gauge needle, the biotinylated H37Rv-
eGFP was incubated with streptavidin-coated microbeads (Milte-
nyi) for 20 minutes at room temperature. The bacteria were
pelleted and again passaged 5–10 times through a 27 gauge needle
to create a single cell suspension. DC were infected, harvested, and
homogenized as above. Phagosomes were purified by passing the
postnuclear supernatant over a Miltenyi MS column on ice. After
3 washes with ice cold PBS, the bound phagosomes were eluted in
0.6 ml PBS as per the manufacturer’s instruction. The purified
phagosomes were used for flow organellometry or in functional
assays as described above.
For EM analysis of percoll and magnetically-isolated phago-
somes, pelleted samples were fixed in 100 mM sodium cacodylate
(pH 7.2), 2.5% glutaraldehyde, 1.6% paraformaldehyde, 0.064%
picric acid, 0.1% ruthenium red, gently washed, and postfixed for
1 hour in 1% osmium tetroxide plus 08% potassium ferricyanide
in 100 mM sodium cacodylate, pH 7.2. After thorough rinsing in
water, samples were prestained in 4% uranyl acetate for 1 hour,
thoroughly rinsed, dehydrated, infiltrated overnight in 1:1
acetone:Epon 812, infiltrated 1 hour with 100% Epon 812 resin,
and embedded in the resin. After polymerization, 60- to 80-nm
thin sections were cut on a Reichert ultramicrotome, stained
5 min in lead citrate, rinsed, poststained 30 min in uranyl acetate,
rinsed, and dried. EM was performed at 60 kV on a Philips
Morgagne TEM, equipped with a CCD, and images were
collected at original magnifications of 1,000–20,0006.
Western blot analysis
After fractionation of percoll-separated postnuclear supernatant
from Mtb–infected DC, fractions containing plasma membrane
(fractions 7–9) or phagosomes (fractions 20–30) were resuspended
in RIPA buffer for lysis. The supernatant was pre-cleared with
isotype antibody (IgG2a, Biolegend) and Protein A/G beads
HLA-I Processing in Mtb-Infected DC
PLoS Pathogens | www.plospathogens.org 11 April 2009 | Volume 5 | Issue 4 | e1000374(Calbiochem) for 1 hour each. Samples were spun and superna-
tant incubated with pan-HLA-I antibody (W6/32, AbD Serotec)
and Protein A/G beads for 1 hour. These immunoprecipiated
samples were then electrophoresed and the proteins blotted onto a
polyvinylidene difluoride membrane (Immobilon-P; Millipore) and
probed with the following antibodies: pan-HLA-I (HC10, kind gift
from Dave Johnson, OHSU), HLA-A2 (HCA2, kind gift from
Peter Creswell, Yale University and Emmanuel Wiertz, Leiden
University), and HLA-E (MEM-E/02, Abcam). They were then
detected using an enhanced chemiluminescence (ECL) kit (Perkin-
Elmer Life Sciences). Gels were scanned into TIFF images and
analyzed via Image J software (available online from National
Institutes of Health).
Statistical analysis
Statistical significance of inhibition was determined using
Student’s two-tailed t test compared to control-treated cells, unless
otherwise indicated.
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